Benaroya Research Institute
Benaroya Research Institute (BRI) is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Carla Greenbaum, MD, the TrialNet team at BRI is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Our Team
Carla Greenbaum, MD
Director, Diabetes Clinical Research Program, TrialNet ChairDr. Greenbaum joined the Benaroya Research Institute (BRI) in 2000, where she is a Member and serves as Director of the Diabetes Research Program and the BRI Clinical Research Center. Dr. Greenbaum serves on the Board of Directors for BRI and is a member of the BRI Institutional Review Board, which provides oversight for clinical studies. She currently serves as Chair of Type 1 Diabetes TrialNet
Sandra Lord, MD
Bao Ng, DNP
Sub-Investigator
Dana VanBuecken, ARNP-BC
Anna Barash
Corinna Tordillos
Kim Varner
Nancy Wickstrom
Katie Bennett
Rishab Kotak
"We want to thank every person who has taken part of research over the past 20 years. Because of their participation, we can now identify the disease in earlier stages, long before symptoms appear. The next step is to find a way to stop the disease from progressing and prevent symptomatic type 1 diabetes." Carla Greenbaum, MD
Regional Affiliates
Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with BRI to offer convenient participation in our research programs
Research Studies
The following studies are actively recruiting participants. Please click on the study title to learn more. For those interested in participation, contact us for more information.
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
TrialNet is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 12 up to 35 who have a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details
TrialNet is testing rituximab-pvvr and abatacept in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D) to learn if using both treatments, one after the other, maintains the body’s ability to make insulin. By adding abatacept after rituximab-pvvr, researchers predict more people will experience prolonged beta cell function during and possibly after treatment. Details
TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details
